A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).